Abstract：
The skin is the first line of defense for the human body and is vulnerable to injury. Various topical or systemic diseases facilitate skin inflammation, and when the intensity or duration of skin injury exceeds the ability of tissue repair, fibrosis, an outcome of a dysregulated tissue-repair response, begins to dominate the repair process. However, existing methods for reducing skin fibrosis are insufficient and cause side effects, highlighting the need for drugs that effectively inhibit skin fibrosis and reduce immunogenicity, inflammation, apoptosis, and pyroptosis. Tetrahedral framework nucleic acids (tFNAs) are DNA nanomaterials that have a unique spatial structure, demonstrate excellent biosecurity, and promote anti-inflammatory, antioxidative, antifibrotic, angiogenic, and skin-wound-healing activities with almost no toxicity. Here, we explored the potential of tFNAs in skin fibrosis therapy in vitro and in vivo. After incubating cells or injecting mice with profibrogenic molecules and tFNAs, we found that the tFNAs inhibited the epithelial-mesenchymal transition, reduced inflammatory factor levels, decreased skin collagen content, and inhibited the pyroptosis pathway. These findings suggest the potential of tFNAs in treating pyroptosis-related diseases.
摘要：
皮肤是人体的第一道防线，容易受伤。各种局部或全身性疾病促进皮肤炎症，当皮肤损伤的强度或持续时间超过组织修复能力时，纤维化，组织修复反应失调的结果，开始主导修复过程。然而,现有的减少皮肤纤维化的方法不足并引起副作用，强调需要有效抑制皮肤纤维化和降低免疫原性的药物，炎症,凋亡，和焦亡。四面体骨架核酸（tFNA）是具有独特空间结构的DNA纳米材料，表现出良好的生物安全性，并促进抗炎，抗氧化，抗纤维化,血管生成,和皮肤伤口愈合活性几乎没有毒性。这里,我们探讨了tFNA在体外和体内皮肤纤维化治疗中的潜力。在孵育细胞或给小鼠注射促纤维化分子和tFNA后，我们发现tFNA抑制上皮-间质转化，降低炎症因子水平，皮肤胶原蛋白含量降低，并抑制焦亡途径。这些发现表明tFNA在治疗焦亡相关疾病中的潜力。
